SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced the upcoming presentations on two of their preclinical programs. TP-0903, an AXL kinase inhibitor, and TP-0184, an ALK-2 kinase inhibitor, are advancing toward first-in-human clinical trials. Preclinical findings will be presented at the 20th Congress of European Hematology Association, EHA, in Vienna Austria, from June 11 through June 14, 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
